$LPTN volume gap candle recovery $3.25 Nasdaq CM
Post# of 98044
Posted On: 08/20/2016 9:48:28 AM
$LPTN volume gap candle recovery $3.25
Nasdaq CM
Website
Ultra Low Float
Shares Outstanding 2.37M
Float 1.91M
% Held by Insiders 14.52%
% Held by Institutions 1 2.60%
Shares Short 72.09k
Short Ratio 0.79
Short % of Float 3 3.55%
Shares Short (prior month) 360.1k
Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. It develops Lpathomab, a humanized monoclonal antibody (mAb) against lysophosphatidic acid that has completed Phase 1a clinical trial for various chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain, and pain associated with lumbosacral radiculopathy. The company also develops iSONEP, a mAb against sphingosine-1-phosphate, which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid sphingosine-1-phosphate (S1P), which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lung cancer, pancreatic cancer, and melanoma. Lpath, Inc. has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.
Nasdaq CM
Website
Ultra Low Float
Shares Outstanding 2.37M
Float 1.91M
% Held by Insiders 14.52%
% Held by Institutions 1 2.60%
Shares Short 72.09k
Short Ratio 0.79
Short % of Float 3 3.55%
Shares Short (prior month) 360.1k
Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. It develops Lpathomab, a humanized monoclonal antibody (mAb) against lysophosphatidic acid that has completed Phase 1a clinical trial for various chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain, and pain associated with lumbosacral radiculopathy. The company also develops iSONEP, a mAb against sphingosine-1-phosphate, which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid sphingosine-1-phosphate (S1P), which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lung cancer, pancreatic cancer, and melanoma. Lpath, Inc. has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.
(0)
(0)Scroll down for more posts ▼